Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tranexamic acid plus cetirizine for chronic urticaria
IRCT20220205053947N1Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, triple-blind trial of tranexamic acid and cetirizine in chronic idiopathic urticaria (CIU) (2 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoints: D-dimer level, Chronic Urticaria Quality of Life questionnaire and 1 more. Started Apr 2022; status: completed.
02
Drugs
tranexamic acidcetirizine
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on IRCT20220205053947N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220205053947N1.